Global Cancer/Tumor Profiling Market Overview
The global cancer/tumor profiling market is experiencing robust growth, driven by the rising prevalence of cancer and the rapid adoption of precision medicine approaches. Valued at USD 12.47 billion in 2024, the market is expected to reach USD 26.29 billion by 2033, expanding at a CAGR of 8.21% during 2025-2033. The increasing integration of genomics and proteomics, along with the growing implementation of biomarker-based diagnostic methods, is fueling market expansion.
In 2024, North America accounted for more than 42.8% of the total market share, supported by a well-developed healthcare infrastructure, early adoption of advanced oncology diagnostics, and substantial investments in R&D initiatives.
Study Assumption Years
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Cancer/Tumor Profiling Market Key Takeaways
- Market Size and Growth: The market was valued at USD 12.47 billion in 2024 and is projected to reach USD 26.29 billion by 2033, growing at a CAGR of 8.21%.
- Regional Leadership: North America led the global market with a 42.8% share in 2024, supported by advanced diagnostic capabilities and technological development.
- Leading Cancer Type: Breast cancer remains the dominant segment due to its high prevalence and increasing use of precision-based treatment models.
- Technological Edge: Next-Generation Sequencing (NGS) continues to be essential for identifying biomarkers and decoding genomic variations.
- Technique Focus: Genomics accounted for 39.8% of the market share in 2024, emphasizing its importance in analyzing genetic mutations and cancer mechanisms.
- Application Scope: Personalized medicine is gaining momentum as it facilitates customized therapeutic approaches for individual patients.
- Emerging Markets: The Asia Pacific region is witnessing accelerated growth due to the rising cancer burden and increased adoption of advanced diagnostic technologies.
Request for a sample copy of this report: https://www.imarcgroup.com/cancer-tumor-profiling-market/requestsample
Market Growth Factors
Technological Advancements in Genomic and Proteomic Profiling
Continuous innovation in genomic and proteomic profiling is transforming cancer diagnostics. Techniques like NGS are enabling precise mutation detection and biomarker identification, enhancing clinical decision-making and supporting the expansion of personalized therapies. Their growing integration into oncology is a major factor driving the market forward.
Rising Cancer Incidence and Personalized Treatment Demand
With an estimated 20 million new cancer cases in 2022 and projections reaching 35 million by 2050, the demand for personalized and effective treatment strategies is increasing significantly. Tumor profiling allows healthcare providers to design individualized therapies based on a patient’s genetic profile, improving treatment outcomes and survival rates.
Government and Institutional Support for Oncology Research
Global governments and private institutions are ramping up investments in oncology research. For instance, the UK Government aims to raise R&D investment to 2.4% of GDP by 2027. These initiatives are fostering innovation in cancer diagnostics and supporting the integration of tumor profiling technologies across clinical practices.
Market Segmentation
By Cancer Type:
- Breast Cancer – Largest segment due to high incidence and growing demand for customized therapies
- Lung Cancer – Rising focus on early detection and targeted drug development
- Colorectal Cancer – Increasing use of molecular diagnostics and personalized medicine
- Prostate Cancer – Improved profiling methods enhancing treatment precision
- Melanoma Cancer – Greater use of genetic profiling for targeted therapy development
- Others – Encompasses additional cancers where profiling applications are expanding
By Technology:
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In-Situ Hybridization (ISH)
- Microarray
- Others
By Technique:
- Genomics – Represented 39.8% of the market share in 2024
- Proteomics
- Epigenetics
- Metabolomics
By Application:
- Personalized Medicine
- Diagnostics
- Biomarker Discovery
- Prognostics
- Others
Breakup by Region
North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa
Regional Insights
North America dominated the global market in 2024, accounting for over 42.8% of total revenue. This dominance stems from the region’s robust healthcare infrastructure, widespread access to genomic diagnostics, and substantial R&D funding. Supportive government initiatives and the presence of key biotechnology companies further strengthen the region’s leadership in the cancer/tumor profiling market.
Recent Developments & News
- October 2024: Illumina partnered with AstraZeneca to co-develop NGS-based companion diagnostics for targeted cancer treatment.
- September 2024: Thermo Fisher introduced the Oncomine Comprehensive Assay Plus to enhance mutation detection in solid tumors.
- November 2023: Illumina unveiled an upgraded version of TruSight Oncology 500 ctDNA v2 for deeper genomic insights through liquid biopsy.
- May 2023: Pfizer and Thermo Fisher Scientific collaborated to expand NGS-based testing accessibility for breast and lung cancer patients across more than 30 countries.
Key Players
- Abbott Laboratories
- Becton Dickinson and Company
- Caris Life Sciences
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
- Hologic Inc.
- HTG Molecular Diagnostics Inc.
- Illumina Inc.
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories
- Qiagen N.V.
- Siemens AG
- Sysmex Corporation
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5231&flag=C
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-201-971-6302
